VistaGen Other Current Liab from 2010 to 2024
| VTGN Stock | USD 3.86 0.03 0.77% |
Other Current Liabilities | First Reported 2008-03-31 | Previous Quarter 292.6 K | Current Value 129.3 K | Quarterly Volatility 797.6 K |
Check VistaGen Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among VistaGen main balance sheet or income statement drivers, such as Interest Expense of 25.1 K, Selling General Administrative of 12.5 M or Other Operating Expenses of 71.3 M, as well as many exotic indicators such as Dividend Yield of 0.0, Average Payables of 0.0 or ROIC of 20.05. VistaGen financial statements analysis is a perfect complement when working with VistaGen Therapeutics Valuation or Volatility modules.
VistaGen | Other Current Liab |
Latest VistaGen Therapeutics' Other Current Liab Growth Pattern
Below is the plot of the Other Current Liab of VistaGen Therapeutics over the last few years. It is VistaGen Therapeutics' Other Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in VistaGen Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Other Current Liab | 10 Years Trend |
|
Other Current Liab |
| Timeline |
VistaGen Other Current Liab Regression Statistics
| Arithmetic Mean | 869,412 | |
| Geometric Mean | 761,712 | |
| Coefficient Of Variation | 49.07 | |
| Mean Deviation | 323,228 | |
| Median | 808,100 | |
| Standard Deviation | 426,650 | |
| Sample Variance | 182B | |
| Range | 1.5M | |
| R-Value | 0.32 | |
| Mean Square Error | 176.6B | |
| R-Squared | 0.1 | |
| Significance | 0.25 | |
| Slope | 30,052 | |
| Total Sum of Squares | 2.5T |
VistaGen Other Current Liab History
About VistaGen Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include VistaGen Therapeutics income statement, its balance sheet, and the statement of cash flows. VistaGen Therapeutics investors use historical funamental indicators, such as VistaGen Therapeutics's Other Current Liab, to determine how well the company is positioned to perform in the future. Although VistaGen Therapeutics investors may use each financial statement separately, they are all related. The changes in VistaGen Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on VistaGen Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on VistaGen Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in VistaGen Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Other Current Liabilities | 905.5 K | 951.2 K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of VistaGen Therapeutics Correlation against competitors. To learn how to invest in VistaGen Stock, please use our How to Invest in VistaGen Therapeutics guide.Note that the VistaGen Therapeutics information on this page should be used as a complementary analysis to other VistaGen Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Complementary Tools for VistaGen Stock analysis
When running VistaGen Therapeutics' price analysis, check to measure VistaGen Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VistaGen Therapeutics is operating at the current time. Most of VistaGen Therapeutics' value examination focuses on studying past and present price action to predict the probability of VistaGen Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VistaGen Therapeutics' price. Additionally, you may evaluate how the addition of VistaGen Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |
Is VistaGen Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of VistaGen Therapeutics. If investors know VistaGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about VistaGen Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.96) | Revenue Per Share 0.077 | Quarterly Revenue Growth 1.291 | Return On Assets (0.26) | Return On Equity (0.45) |
The market value of VistaGen Therapeutics is measured differently than its book value, which is the value of VistaGen that is recorded on the company's balance sheet. Investors also form their own opinion of VistaGen Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is VistaGen Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because VistaGen Therapeutics' market value can be influenced by many factors that don't directly affect VistaGen Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between VistaGen Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if VistaGen Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, VistaGen Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.